- testing |
| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 4 Nov 2025 | 23 Oct 2025 |
| Alembic Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2025 ,inter alia, to consider and approve With reference to the captioned matter, the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Tuesday, 4th November 2025 inter-alia to consider and approve Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2025. Please find attached unaudited financial results for the quarter and half year ended 30th September, 2025 Unaudited Financial Results For The Quarter and Half Year Ended 30Th September, 2025 (As Per BSE Announcement Dated on: 04/11/2025) | ||
| Board Meeting | 5 Aug 2025 | 21 Jul 2025 |
| Alembic Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2025 ,inter alia, to consider and approve Unaudited Financial Results of the Company for the quarter ended 30th June, 2025 Please find enclosed the Outcome of Board meeting Please find the updated Contact details of KMP and senior officials pursuant to Reg 30 (5) of SEBI LODR Regulations, 2015. (As per BSE Announcement Dated on 05.08.2025) | ||
| Board Meeting | 6 May 2025 | 18 Apr 2025 |
| Alembic Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/05/2025 inter alia to consider and approve With reference to the captioned matter the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Tuesday 6th May 2025 Please find attached herewith the Financial Results for the quarter and Financial Year ended 31st March, 2025 Outcome of Board Meeting (As Per BSE Announcement Dated on 05.05.2025) | ||
| Board Meeting | 3 Feb 2025 | 22 Jan 2025 |
| ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2025 inter alia to consider and approve Unaudited Financial Results for the quarter and nine months ended 31st December 2024 Please find the outcome of the meeting. (As per BSE Announcement Dated on 03/02/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.